Skip to main content
SpringerLink
Log in

Viral Hepatitis C

  • Chapter
  • First Online:
Molecular Pathology of Liver Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 5))

Abstract

Chronic hepatitis C is a viral infection characterized by a chronic inflammatory liver disease that frequently leads to cirrhosis and hepatocellular carcinoma. The liver disease is initiated by a host immune response to viral infection of hepatocytes that is ineffective in clearing the virus in at least half of the cases. Once chronic infection is established, the virus modulates host-cell signaling and the metabolic processes that produce lipid accumulation, oxidative stress, insulin resistance, cell-cycle checkpoint disturbances, and fibrogenesis. Some of these effects are secondary to cytokines secreted by infected hepatocytes and immune cells, but others are direct effects of viral proteins on cell processes. This review summarizes the current understanding of the mechanisms by which HCV produces its effects on the liver and the significance of these to disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.

    PubMed  Google Scholar 

  2. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.

    PubMed  Google Scholar 

  3. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.

    PubMed  Google Scholar 

  4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453–63.

    PubMed  CAS  Google Scholar 

  5. Stamataki Z, Grove J, Balfe P, McKeating JA. Hepatitis C virus entry and neutralization. Clin Liver Dis. 2008;12(3):693–712. x.

    PubMed  Google Scholar 

  6. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–52.

    PubMed  CAS  Google Scholar 

  7. Tellinghuisen TL, Rice CM. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002;5(4):419–27.

    PubMed  CAS  Google Scholar 

  8. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26(2):485–90.

    PubMed  CAS  Google Scholar 

  9. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–8.

    PubMed  CAS  Google Scholar 

  10. Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005;25(1):105–17.

    PubMed  CAS  Google Scholar 

  11. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis. 1995;15(1):70–81.

    PubMed  CAS  Google Scholar 

  12. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.

    PubMed  Google Scholar 

  13. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34(5):730–9.

    PubMed  CAS  Google Scholar 

  14. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89(1):53–9.

    PubMed  CAS  Google Scholar 

  15. Yoneyama M. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 2004;5:730–7.

    CAS  Google Scholar 

  16. Su AI. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. 2002;99:15669–74.

    PubMed  CAS  Google Scholar 

  17. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002;99(24):15661–8.

    PubMed  CAS  Google Scholar 

  18. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194(10):1395–406.

    PubMed  CAS  Google Scholar 

  19. Golden-Mason L, Castelblanco N, O’Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol. 2007;81(17):9292–8.

    PubMed  CAS  Google Scholar 

  20. Gale Jr M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436(7053):939–45.

    PubMed  CAS  Google Scholar 

  21. Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl. 2006;12(3):363–72.

    PubMed  Google Scholar 

  22. Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol. 2003;38(1):67–75.

    PubMed  CAS  Google Scholar 

  23. Gremion C, Grabscheid B, Wolk B, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol. 2004;78(4):2152–7.

    PubMed  CAS  Google Scholar 

  24. Wang J, Holmes TH, Cheung R, Greenberg HB, He XS. Expression of chemokine receptors on intrahepatic and peripheral lymphocytes in chronic hepatitis C infection: its relationship to liver inflammation. J Infect Dis. 2004;190(5):989–97.

    PubMed  CAS  Google Scholar 

  25. Abrignani S. Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis. Dev Biol Stand. 1998;92:191–4.

    PubMed  CAS  Google Scholar 

  26. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75(15):7059–66.

    PubMed  CAS  Google Scholar 

  27. Bowen DG, Warren A, Davis T, et al. Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology. 2002;123(4):1252–64.

    PubMed  CAS  Google Scholar 

  28. Ohta A, Sekimoto M, Sato M, et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol. 2000;165(2):956–61.

    PubMed  CAS  Google Scholar 

  29. Mochizuki K, Hayashi N, Katayama K, et al. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology. 1997;25(3):713–8.

    PubMed  CAS  Google Scholar 

  30. Shiraki K, Sugimoto K, Okano H, et al. CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med. 2006;18(4):559–63.

    PubMed  CAS  Google Scholar 

  31. Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol. 1999;163(6):3202–10.

    PubMed  CAS  Google Scholar 

  32. Sun J, Tumurbaatar B, Jia J, et al. Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury. J Virol. 2005;79(16):10730–9.

    PubMed  CAS  Google Scholar 

  33. Pillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat. 2007;14(5):318–29.

    PubMed  Google Scholar 

  34. Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis. 2007;195(6):857–63.

    PubMed  Google Scholar 

  35. Puig M, Mihalik K, Tilton JC, et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology. 2006;44(3):736–45.

    PubMed  CAS  Google Scholar 

  36. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659–62.

    PubMed  CAS  Google Scholar 

  37. Smyk-Pearson S, Tester IA, Klarquist J, et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol. 2008;82(4):1827–37.

    PubMed  CAS  Google Scholar 

  38. Schulze zur Wiesch J, Lauer GM, Day CL, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005;175(6):3603–13.

    PubMed  CAS  Google Scholar 

  39. Suvas S, Azkur AK, Kim BS, Kumaraguru U, Rouse BT. CD4(+)CD25(+) regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol. 2004;172(7):4123–32.

    PubMed  CAS  Google Scholar 

  40. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38(6):1437–48.

    PubMed  Google Scholar 

  41. Heeg MHJ, Ulsenheimer A, Grüner NH, et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology. 2009;137(4):1280-8.

    Google Scholar 

  42. Bowen DG, Shoukry NH, Grakoui A, et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol. 2008;82(10):5109–14.

    PubMed  CAS  Google Scholar 

  43. Smyk-Pearson S, Golden-Mason L, Klarquist J, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008;197(1):46–57.

    PubMed  CAS  Google Scholar 

  44. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol. 2007;81(17):9249–58.

    PubMed  CAS  Google Scholar 

  45. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008;180(6):3637–41.

    PubMed  CAS  Google Scholar 

  46. Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119(3):551–64.

    PubMed  CAS  Google Scholar 

  47. Mengshol JA, Golden-Mason L, Castelblanco N, et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut. 2009;58(7):964–73.

    PubMed  CAS  Google Scholar 

  48. Goutagny N, Vieux C, Decullier E, et al. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis. 2004;189(9):1646–55.

    PubMed  Google Scholar 

  49. Liang H, Russell RS, Yonkers NL, et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol. 2009;83(11):5693–707.

    PubMed  CAS  Google Scholar 

  50. Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One. 2009;4(2):e4319.

    PubMed  Google Scholar 

  51. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology. 2008;47(2):385–95.

    PubMed  CAS  Google Scholar 

  52. Sarobe P, Lasarte JJ, Casares N, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol. 2002;76(10):5062–70.

    PubMed  CAS  Google Scholar 

  53. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Mandrekar P, Szabo G. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res. 2003;27(6):1023–31.

    PubMed  CAS  Google Scholar 

  54. Dolganiuc A, Chang S, Kodys K, et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177(10):6758–68.

    PubMed  CAS  Google Scholar 

  55. Saito K, Ait-Goughoulte M, Truscott SM, et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol. 2008;82(7):3320–8.

    PubMed  CAS  Google Scholar 

  56. Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology. 2008;135(6):2119–27.

    PubMed  CAS  Google Scholar 

  57. Decalf J, Fernandes S, Longman R, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007;204(10):2423–37.

    PubMed  CAS  Google Scholar 

  58. Gehring S, Gregory SH, Wintermeyer P, Aloman C, Wands JR. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol. 2009;16(2):163–71.

    PubMed  CAS  Google Scholar 

  59. Thomson M, Nascimbeni M, Havert MB, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol. 2003;77(2):862–70.

    PubMed  CAS  Google Scholar 

  60. Deignan T, Curry MP, Doherty DG, et al. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol. 2002;37(1):101–8.

    PubMed  CAS  Google Scholar 

  61. Durante-Mangoni E, Wang R, Shaulov A, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol. 2004;173(3):2159–66.

    PubMed  CAS  Google Scholar 

  62. Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet. 2005;365(9464):1062–72.

    PubMed  CAS  Google Scholar 

  63. Kinebuchi M, Matsuura A, Ohya K, Abo W, Kitazawa J. Contribution of Va24Vb11 natural killer T cells in Wilsonian hepatitis. Clin Exp Immunol. 2005;139(1):144–51.

    PubMed  CAS  Google Scholar 

  64. Liu Z, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology. 2004;127(6):1760–74.

    PubMed  CAS  Google Scholar 

  65. Forestier C, Molano A, Im JS, et al. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black × New Zealand White)F1 mice. J Immunol. 2005;175(2):763–70.

    PubMed  CAS  Google Scholar 

  66. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97(10):5498–503.

    PubMed  CAS  Google Scholar 

  67. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology. 2000;31(3):633–40.

    PubMed  CAS  Google Scholar 

  68. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195(1):35–41.

    PubMed  CAS  Google Scholar 

  69. Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol. 2003;77(15):8299–309.

    PubMed  CAS  Google Scholar 

  70. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872–4.

    PubMed  CAS  Google Scholar 

  71. Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J Clin Invest. 2000;105(7):985–93.

    PubMed  CAS  Google Scholar 

  72. Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol. 2000;164(12):6480–6.

    PubMed  CAS  Google Scholar 

  73. Frese M, Schwèarzle V, Barth K, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology. 2002;35(3):694–703.

    PubMed  CAS  Google Scholar 

  74. Betts MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004;172(10):6407–17.

    PubMed  CAS  Google Scholar 

  75. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003;18(4):386–92.

    PubMed  CAS  Google Scholar 

  76. Perlemuter G, Letteron P, Carnot F, et al. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol. 2003;39(6):1020–7.

    PubMed  CAS  Google Scholar 

  77. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology. 2004;39(5):1220–9.

    PubMed  CAS  Google Scholar 

  78. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163(11):6236–43.

    PubMed  CAS  Google Scholar 

  79. Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48(5):1440–50.

    PubMed  CAS  Google Scholar 

  80. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106(4):1175–82.

    PubMed  CAS  Google Scholar 

  81. Helbig KJ, Ruszkiewicz A, Lanford RE, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol. 2009;83(2):836–46.

    PubMed  CAS  Google Scholar 

  82. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617–25.

    PubMed  CAS  Google Scholar 

  83. Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology. 1995;26(4):297–309.

    PubMed  CAS  Google Scholar 

  84. Hu KQ, Currie SL, Shen H, et al. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52(2):570–8.

    PubMed  Google Scholar 

  85. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002;36(3):729–36.

    PubMed  Google Scholar 

  86. Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 2002;17(8):873–81.

    PubMed  Google Scholar 

  87. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16(2):190–5.

    PubMed  CAS  Google Scholar 

  88. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15(4):572–7.

    PubMed  CAS  Google Scholar 

  89. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology. 1993;104(2):595–603.

    PubMed  CAS  Google Scholar 

  90. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126(2):586–97.

    PubMed  CAS  Google Scholar 

  91. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005;100(3):711–5.

    PubMed  Google Scholar 

  92. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33(1):106–15.

    PubMed  CAS  Google Scholar 

  93. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36(5):1266–72.

    PubMed  Google Scholar 

  94. Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology. 2001;39(2):119–24.

    PubMed  CAS  Google Scholar 

  95. Fujie H, Yotsuyanagi H, Moriya K, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol. 1999;59(2):141–5.

    PubMed  CAS  Google Scholar 

  96. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15(2):129–36.

    PubMed  CAS  Google Scholar 

  97. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416–23.

    PubMed  CAS  Google Scholar 

  98. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695–704.

    PubMed  CAS  Google Scholar 

  99. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203.

    PubMed  Google Scholar 

  100. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103(5):1136–44.

    PubMed  CAS  Google Scholar 

  101. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003–8.

    PubMed  CAS  Google Scholar 

  102. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29 Suppl 2:13–25.

    PubMed  CAS  Google Scholar 

  103. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636–42.

    PubMed  Google Scholar 

  104. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484–90.

    PubMed  Google Scholar 

  105. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41(1):82–7.

    PubMed  Google Scholar 

  106. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16(7):492–9.

    PubMed  CAS  Google Scholar 

  107. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;37(6):837–42.

    PubMed  Google Scholar 

  108. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52(2):288–92.

    PubMed  CAS  Google Scholar 

  109. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology. 2006;44(6):1648–55.

    PubMed  CAS  Google Scholar 

  110. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. 2008;48(3):723–31.

    PubMed  Google Scholar 

  111. Nieminen U, Arkkila PE, Karkkainen P, Farkkila MA. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int. 2009;29(2):153–8.

    PubMed  Google Scholar 

  112. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78(Pt 7):1527–31.

    PubMed  CAS  Google Scholar 

  113. Chang ML, Yeh CT, Chen JC, et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics. 2008;9:109.

    PubMed  Google Scholar 

  114. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002;122(2):352–65.

    PubMed  CAS  Google Scholar 

  115. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A. 1997;94(4):1200–5.

    PubMed  CAS  Google Scholar 

  116. McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta. 2009;1791(6):552–9.

    PubMed  CAS  Google Scholar 

  117. Roingeard P, Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat. 2008;15(3):157–64.

    PubMed  CAS  Google Scholar 

  118. Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005;42(5):744–51.

    PubMed  CAS  Google Scholar 

  119. Piodi A, Chouteau P, Lerat H, Hezode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology. 2008;48(1):16–27.

    PubMed  CAS  Google Scholar 

  120. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis. 2008;197(2):283–91.

    PubMed  CAS  Google Scholar 

  121. Hourioux C, Patient R, Morin A, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut. 2007;56(9):1302–8.

    PubMed  CAS  Google Scholar 

  122. Wang AG, Lee DS, Moon HB, et al. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol. 2009;219(2):253–62.

    PubMed  CAS  Google Scholar 

  123. Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology. 1999;30(4):1064–76.

    PubMed  CAS  Google Scholar 

  124. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16(2):185–94.

    PubMed  CAS  Google Scholar 

  125. Fukasawa M, Tanaka Y, Sato S, et al. Enhancement of de novo fatty acid biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core protein. Biol Pharm Bull. 2006;29(9):1958–61.

    PubMed  CAS  Google Scholar 

  126. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol. 2007;46(6):999–1008.

    PubMed  CAS  Google Scholar 

  127. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol. 2007;81(15):8122–30.

    PubMed  CAS  Google Scholar 

  128. Oem JK, Jackel-Cram C, Li YP, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol. 2008;89(Pt 5):1225–30.

    PubMed  CAS  Google Scholar 

  129. Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A. 2007;104(5):1661–6.

    PubMed  CAS  Google Scholar 

  130. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun. 2007;355(4):883–8.

    PubMed  CAS  Google Scholar 

  131. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem. 2009;284(14):9237–46.

    PubMed  CAS  Google Scholar 

  132. McPherson S, Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol. 2008;49(6):1046–54.

    PubMed  CAS  Google Scholar 

  133. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118(2):683–94.

    PubMed  Google Scholar 

  134. Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. 2002;35(4):937–46.

    PubMed  CAS  Google Scholar 

  135. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128(2):334–42.

    PubMed  CAS  Google Scholar 

  136. Yamaguchi A, Tazuma S, Nishioka T, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci. 2005;50(7):1361–71.

    PubMed  CAS  Google Scholar 

  137. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009;583(17):2720–6.

    PubMed  CAS  Google Scholar 

  138. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384–92.

    PubMed  CAS  Google Scholar 

  139. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6.

    PubMed  Google Scholar 

  140. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–508.

    PubMed  CAS  Google Scholar 

  141. Hung CH, Lee CM, Chen CH, et al. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int. 2009;29(7):1086–93.

    PubMed  CAS  Google Scholar 

  142. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003;98(12):2751–6.

    PubMed  CAS  Google Scholar 

  143. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096–101.

    PubMed  CAS  Google Scholar 

  144. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.

    PubMed  CAS  Google Scholar 

  145. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621–5.

    PubMed  CAS  Google Scholar 

  146. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol. 2007;81(4):1727–35.

    PubMed  CAS  Google Scholar 

  147. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277(44):42394–8.

    PubMed  CAS  Google Scholar 

  148. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004;101(28):10422–7.

    PubMed  CAS  Google Scholar 

  149. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45(5):1164–71.

    PubMed  CAS  Google Scholar 

  150. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol. 2006;21 Suppl 3:S34–7.

    PubMed  CAS  Google Scholar 

  151. Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2006;34(2):65–73.

    PubMed  CAS  Google Scholar 

  152. Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res. 2002;36(9):939–48.

    PubMed  CAS  Google Scholar 

  153. Vidali M, Tripodi MF, Ivaldi A, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 2008;48(3):399–406.

    PubMed  CAS  Google Scholar 

  154. Mitsuyoshi H, Itoh Y, Sumida Y, et al. Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res. 2008;38(4):348–53.

    PubMed  CAS  Google Scholar 

  155. Maki A, Kono H, Gupta M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007;14(3):1182–90.

    PubMed  Google Scholar 

  156. Bureau C, Bernad J, Chaouche N, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001;276(25):23077–83.

    PubMed  CAS  Google Scholar 

  157. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134(1):226–38.

    PubMed  CAS  Google Scholar 

  158. Benali-Furet NL, Chami M, Houel L, et al. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene. 2005;24(31):4921–33.

    PubMed  CAS  Google Scholar 

  159. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 2005;13(4):159–63.

    PubMed  CAS  Google Scholar 

  160. Qadri I, Iwahashi M, Capasso JM, et al. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 2004;378(Pt 3):919–28.

    PubMed  CAS  Google Scholar 

  161. Piccoli C, Scrima R, Quarato G, et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology. 2007;46(1):58–65.

    PubMed  CAS  Google Scholar 

  162. Schwer B, Ren S, Pietschmann T, et al. Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol. 2004;78(15):7958–68.

    PubMed  CAS  Google Scholar 

  163. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem. 2005;280(45):37481–8.

    PubMed  CAS  Google Scholar 

  164. Li Y, Boehning DF, Qian T, Popov VL, Weinman SA. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J. 2007;21(10):2474–85.

    PubMed  CAS  Google Scholar 

  165. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A. 2001;98(17):9599–604.

    PubMed  CAS  Google Scholar 

  166. Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, et al. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol. 2009;50(5):872–82.

    PubMed  CAS  Google Scholar 

  167. Horner SM, Gale Jr M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009;29(9):489–98.

    PubMed  CAS  Google Scholar 

  168. Nomura-Takigawa Y, Nagano-Fujii M, Deng L, et al. Non-structural protein 4A of hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J Gen Virol. 2006;87(Pt 7):1935–45.

    PubMed  CAS  Google Scholar 

  169. Selimovic D, Hassan M. Inhibition of hepatitis C virus (HCV) core protein-induced cell growth by non-structural protein 4A (NS4A) is mediated by mitochondrial dysregulation. Bosn J Basic Med Sci. 2008;8(1):4–11.

    PubMed  Google Scholar 

  170. Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol. 2008;103(1):147–53.

    PubMed  CAS  Google Scholar 

  171. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G847–51.

    PubMed  CAS  Google Scholar 

  172. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.

    PubMed  CAS  Google Scholar 

  173. van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12(4):805–24. ix.

    PubMed  Google Scholar 

  174. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22 Suppl 1:S73–8.

    PubMed  CAS  Google Scholar 

  175. Urtasun R, Conde de la Rosa L, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis. 2008;12(4):769–90. viii.

    PubMed  CAS  Google Scholar 

  176. Taniguchi H, Kato N, Otsuka M, et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol. 2004;72(1):52–9.

    PubMed  CAS  Google Scholar 

  177. Nelson DR, Gonzalez-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat. 1997;4(1):29–35.

    PubMed  CAS  Google Scholar 

  178. Gabriel A, Ziolkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res. 2008;38(2):141–6.

    PubMed  Google Scholar 

  179. Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology. 2005;129(1):246–58.

    PubMed  CAS  Google Scholar 

  180. Deng L, Adachi T, Kitayama K, et al. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol. 2008;82(21):10375–85.

    PubMed  CAS  Google Scholar 

  181. Zhu H, Dong H, Eksioglu E, et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology. 2007;133(5):1649–59.

    PubMed  CAS  Google Scholar 

  182. Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46(5):1509–18.

    PubMed  CAS  Google Scholar 

  183. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529–40.

    PubMed  CAS  Google Scholar 

  184. Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med. 2005;37(2):138–45.

    PubMed  CAS  Google Scholar 

  185. Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 2008;14 Suppl 2:S27–35.

    PubMed  Google Scholar 

  186. Gatza ML, Chandhasin C, Ducu RI, Marriott SJ. Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environ Mol Mutagen. 2005;45(2–3):304–25.

    PubMed  CAS  Google Scholar 

  187. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782(3):127–50.

    PubMed  CAS  Google Scholar 

  188. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology. 2000;271(1):197–204.

    PubMed  CAS  Google Scholar 

  189. Ruggieri A, Murdolo M, Harada T, Miyamura T, Rapicetta M. Cell cycle perturbation in a human hepatoblastoma cell line constitutively expressing Hepatitis C virus core protein. Arch Virol. 2004;149(1):61–74.

    PubMed  CAS  Google Scholar 

  190. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology. 1999;258(1):100–7.

    PubMed  CAS  Google Scholar 

  191. Zemel R, Gerechet S, Greif H, et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat. 2001;8(2):96–102.

    PubMed  CAS  Google Scholar 

  192. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol. 1995;69(6):3893–6.

    PubMed  CAS  Google Scholar 

  193. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol. 1999;80(Pt 5):1179–83.

    PubMed  CAS  Google Scholar 

  194. Sun BS, Pan J, Clayton MM, et al. Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol. 2004;201(3):447–58.

    PubMed  CAS  Google Scholar 

  195. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004;101(12):4262–7.

    PubMed  CAS  Google Scholar 

  196. Gurtsevitch VE. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc). 2008;73(5):504–13.

    CAS  Google Scholar 

  197. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4(9):1065–7.

    PubMed  CAS  Google Scholar 

  198. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351(6324):317–20.

    PubMed  CAS  Google Scholar 

  199. Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106(5):1548–53.

    PubMed  CAS  Google Scholar 

  200. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat. 2003;21(3):201–16.

    PubMed  CAS  Google Scholar 

  201. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S62–71.

    PubMed  CAS  Google Scholar 

  202. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005;331(3):851–8.

    PubMed  CAS  Google Scholar 

  203. Lan KH, Sheu ML, Hwang SJ, et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene. 2002;21(31):4801–11.

    PubMed  CAS  Google Scholar 

  204. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol. 2001;75(3):1401–7.

    PubMed  CAS  Google Scholar 

  205. Siavoshian S, Abraham JD, Thumann C, Kieny MP, Schuster C. Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol. 2005;75(3):402–11.

    PubMed  CAS  Google Scholar 

  206. Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer. 2003;107(1):65–73.

    PubMed  CAS  Google Scholar 

  207. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem. 1997;272(17):10983–6.

    PubMed  CAS  Google Scholar 

  208. Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene. 1998;208(2):331–6.

    PubMed  CAS  Google Scholar 

  209. Lu W, Lo SY, Chen M, Wu K, Fung YK, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology. 1999;264(1):134–41.

    PubMed  CAS  Google Scholar 

  210. Otsuka M, Kato N, Lan K, et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem. 2000;275(44):34122–30.

    PubMed  CAS  Google Scholar 

  211. Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene. 2004;23(14):2472–83.

    PubMed  CAS  Google Scholar 

  212. Banerjee A, Saito K, Meyer K, et al. Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. J Virol. 2009;83(19):9663–71.

    PubMed  CAS  Google Scholar 

  213. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol. 2001;82(Pt 9):2235–41.

    PubMed  CAS  Google Scholar 

  214. Wang F, Yoshida I, Takamatsu M, et al. Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochem Biophys Res Commun. 2000;273(2):479–84.

    PubMed  CAS  Google Scholar 

  215. Honda M, Kaneko S, Shimazaki T, et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology. 2000;31(6):1351–9.

    PubMed  CAS  Google Scholar 

  216. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis. 1999;19(3):235–42.

    PubMed  CAS  Google Scholar 

  217. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2002;8(4):638–43.

    PubMed  CAS  Google Scholar 

  218. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol. 2002;14(6):684–91.

    PubMed  CAS  Google Scholar 

  219. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. Oct 1 2000;14(19):2393–2409.

    Google Scholar 

  220. Cho J, Baek W, Yang S, Chang J, Sung YC, Suh M. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochim Biophys Acta. 2001;1538(1):59–66.

    PubMed  CAS  Google Scholar 

  221. Tsukiyama-Kohara K, Tone S, Maruyama I, et al. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem. 2004;279(15):14531–41.

    PubMed  CAS  Google Scholar 

  222. Munakata T, Nakamura M, Liang Y, Li K, Lemon SM. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A. 2005;102(50):18159–64.

    PubMed  CAS  Google Scholar 

  223. Munakata T, Liang Y, Kim S, et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007;3(9):1335–47.

    PubMed  CAS  Google Scholar 

  224. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med. 2006;6(7):739–48.

    PubMed  CAS  Google Scholar 

  225. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220–7.

    PubMed  CAS  Google Scholar 

  226. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell. 1997;88(3):315–21.

    PubMed  CAS  Google Scholar 

  227. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–30.

    PubMed  CAS  Google Scholar 

  228. Keyomarsi K, Conte Jr D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene. 1995;11(5):941–50.

    PubMed  CAS  Google Scholar 

  229. Nielsen NH, Arnerlov C, Cajander S, Landberg G. Cyclin E expression and proliferation in breast cancer. Anal Cell Pathol. 1998;17(3):177–88.

    PubMed  CAS  Google Scholar 

  230. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol. 1997;17(1):453–9.

    PubMed  CAS  Google Scholar 

  231. Cho JW, Baek WK, Suh SI, et al. Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver. 2001;21(2):137–42.

    PubMed  CAS  Google Scholar 

  232. Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2003;9(9):3389–96.

    PubMed  CAS  Google Scholar 

  233. Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem. 2005;280(36):31548–56.

    PubMed  CAS  Google Scholar 

  234. Wu TH, Yang RL, Xie LP, et al. Inhibition of cell growth and induction of G1-phase cell cycle arrest in hepatoma cells by steroid extract from Meretrix meretrix. Cancer Lett. 2006;232(2):199–205.

    PubMed  CAS  Google Scholar 

  235. Matsuda Y, Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med Mol Morphol. 2006;39(4):169–75.

    PubMed  Google Scholar 

  236. Li X, Hui AM, Sun L, et al. p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res. 2004;10(22):7484–9.

    PubMed  CAS  Google Scholar 

  237. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–14.

    PubMed  CAS  Google Scholar 

  238. Yao YJ, Ping XL, Zhang H, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene. 1999;18(20):3181–5.

    PubMed  CAS  Google Scholar 

  239. Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP, Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol. 2007;13(34):4554–9.

    PubMed  Google Scholar 

  240. Dong-Dong L, Xi-Ran Z, Xiang-Rong C. Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med. 2003;7(1):67–71.

    PubMed  Google Scholar 

  241. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563–8.

    PubMed  CAS  Google Scholar 

  242. Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A. 2004;101(7):2082–7.

    PubMed  CAS  Google Scholar 

  243. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113(12):1774–83.

    PubMed  CAS  Google Scholar 

  244. Tate G, Suzuki T, Mitsuya T. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007;178(2):160–2.

    PubMed  CAS  Google Scholar 

  245. Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67(7):2922–6.

    PubMed  CAS  Google Scholar 

  246. Rahman MA, Kyriazanos ID, Ono T, et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002;100(2):152–7.

    PubMed  CAS  Google Scholar 

  247. Tsutsumi T, Suzuki T, Moriya K, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology. 2003;38(4):820–8.

    PubMed  CAS  Google Scholar 

  248. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem. 2003;278(20):17775–84.

    PubMed  CAS  Google Scholar 

  249. Hassan M, Ghozlan H, Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology. 2005;333(2):324–36.

    PubMed  CAS  Google Scholar 

  250. Zhao LJ, Wang L, Ren H, et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res. 2005;305(1):23–32.

    PubMed  CAS  Google Scholar 

  251. Sato Y, Kato J, Takimoto R, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut. 2006;55(12):1801–8.

    PubMed  CAS  Google Scholar 

  252. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48(1):83–90.

    PubMed  CAS  Google Scholar 

  253. Koike K, Tsutsumi T, Miyoshi H, et al. Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis. J Gastroenterol Hepatol. 2008;23 Suppl 1:S87–91.

    PubMed  CAS  Google Scholar 

  254. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–51.

    PubMed  CAS  Google Scholar 

  255. Fujie H, Moriya K, Shintani Y, et al. Frequent beta-catenin aberration in human hepatocellular carcinoma. Hepatol Res. 2001;20(1):39–51.

    PubMed  CAS  Google Scholar 

  256. Edamoto Y, Hara A, Biernat W, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer. 2003;106(3):334–41.

    PubMed  CAS  Google Scholar 

  257. Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol. 2005;79(8):5006–16.

    PubMed  CAS  Google Scholar 

  258. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52.

    PubMed  CAS  Google Scholar 

  259. Calvisi DF, Ladu S, Conner EA, Factor VM, Thorgeirsson SS. Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest. 2004;84(9):1137–47.

    PubMed  CAS  Google Scholar 

  260. Kwon GY, Yoo BC, Koh KC, Cho JW, Park WS, Park CK. Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci. 2005;20(2):242–7.

    PubMed  CAS  Google Scholar 

  261. Iso Y, Sawada T, Okada T, Kubota K. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol. 2005;92(4):304–11.

    PubMed  CAS  Google Scholar 

  262. Lee HH, Uen YH, Tian YF, et al. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1562–9.

    PubMed  CAS  Google Scholar 

  263. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 2003;163(3):1101–7.

    PubMed  CAS  Google Scholar 

  264. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46(1):48–57.

    PubMed  CAS  Google Scholar 

  265. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129(5):1375–83.

    PubMed  CAS  Google Scholar 

  266. Battaglia S, Benzoubir N, Nobilet S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One. 2009;4(2):e4355.

    PubMed  Google Scholar 

  267. Lilley CE, Schwartz RA, Weitzman MD. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 2007;15(3):119–26.

    PubMed  CAS  Google Scholar 

  268. Ariumi Y, Kuroki M, Dansako H, et al. The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. J Virol. 2008;82(19):9639–46.

    PubMed  CAS  Google Scholar 

  269. Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM. Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA ­damage and mutations of cellular genes. J Virol. 2004;78(16):8835–43.

    PubMed  CAS  Google Scholar 

  270. Myong S, Bruno MM, Pyle AM, Ha T. Spring-loaded mechanism of DNA unwinding by hepatitis C virus NS3 helicase. Science. 2007;317(5837):513–6.

    PubMed  CAS  Google Scholar 

  271. Pang PS, Jankowsky E, Planet PJ, Pyle AM. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 2002;21(5):1168–76.

    PubMed  CAS  Google Scholar 

  272. Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology. 2008;370(2):295–309.

    PubMed  CAS  Google Scholar 

  273. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core ­protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol. 1996;70(7):4438–43.

    PubMed  CAS  Google Scholar 

  274. Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641–53.

    PubMed  CAS  Google Scholar 

  275. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol. 1999;73(6):4713–20.

    PubMed  CAS  Google Scholar 

  276. Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol. 1998;72(5):3691–7.

    PubMed  CAS  Google Scholar 

  277. Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem. 2001;276(15):12140–6.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Work from the author’s laboratories was supported by NIH grants AA012863 (SW) and AI069142 (JS). We gratefully acknowledge Mardelle Susman and Elizabeth Zeller-Last for assistance with manuscript preparation.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA

    Steven A. Weinman

Authors
  1. Jiaren Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaurav Chaturvedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven A. Weinman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven A. Weinman .

Editor information

Editors and Affiliations

  1. School of Medicine, Dept. Pathology, University of Pittsburgh, 200 Lothrop Street, S421-BST, Pittsburgh, 15261, Pennsylvania, USA

    Satdarshan P. S. Monga

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sun, J., Chaturvedi, G., Weinman, S.A. (2011). Viral Hepatitis C. In: Monga, S. (eds) Molecular Pathology of Liver Diseases. Molecular Pathology Library, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7107-4_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7107-4_38

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-7106-7

  • Online ISBN: 978-1-4419-7107-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation